Variations in Cannabinoid Reporting: Part One
Based on a presentation to the American Chemical Society Fall Conference, 2016
by Savino Sguera
In all laboratory analyses, a degree of variation will always exist between the results of any two identical samples. For example, two environmental laboratories that are looking for the toxic metal lead may find slightly different amounts of lead in the same sample. In the environmental testing industry, this variation is kept at a negligibly small value via strict quality control measures which makes slight differences a non-issue.
In the cannabis industry, which is an industry with highly variable regulation, differences of over 30% are detected routinely. While plant products always contain some natural variation (typically less than 15%), much of this variation is due either to negligence or intentional manipulation. In this article, we will examine some of the different sources of variation in THCA/THC reporting. We use THCA/THC reporting as an example, although the same principles hold for any potency or contamination analysis.
As cannabis becomes a mainstream medical option and more patients come to rely upon it, there will be a need to increase the precision and accuracy of cannabis laboratories. This will most likely be done by an increase in laboratory standards, training and qualification, certification, and proper laboratory audits.
“Never attribute to malice that which is adequately explained by stupidity”Hanlon's Razor
One of the most important causes of the wide variation in cannabinoid reporting is inflation. Reporting inflation is a process by which laboratories manipulate or modify the process of their analysis or reporting to increase the final reported value. This often comes at the expense of accuracy, and is motivated by a desire to gain an edge over competition. Laboratories are also pressured to inflate potency numbers by their clients, who are in turn pressured by market forces and unscrupulous distributors. These clients use high THC numbers as a sales tactic to sell products and increase prices. The patients and customers who spend money on mislabeled products are ultimately the ones who suffer from this bad practice.
But how can we confidently say that inflation is occurring? How do we know that variations in lab results are not the product of incompetence? The answer lies in the variation data. Close examination can tell whether the variation appears random or manipulated.
As an example, we used some reported THCA values from medical flowers sold in the state of Nevada in 2016. At the time there was concern among the public that numbers were being manipulated, as products were being sold with labels claiming over 35% THCA in some cases, which had never been seen before anywhere and also doesn’t make biological sense. Plants don’t produce such a disproportionate amount of one chemical.
As a result of this information, an inquiry was called for and the state set up a round-robin program to assess the performance of different laboratories by distributing the same homogenized sample to all parties and assessing the variation. THC results in Nevada have since stabilized at believable values.
If incompetence could explain the variation seen in Figure 1, we would see random variation in either direction, both positive and negative. What we see instead is a manipulated appearance, with Las Vegas numbers almost exclusively appearing above the national average. The only exception is the pre-98 Bubba Kush, which is 0.1% lower than the national average.
The average deviation is +25%, meaning the results from Las Vegas are on average 25% higher than those in other states for a given strain. Some are even reported as high as 50% over the national average. If the data were not manipulated, we would expect to see some samples at -25% and -50%, which is not observed. The only other possibility would be if every grower in Nevada had some secret method that dramatically increases cannabinoid yields on their plants. As far as I’m aware, no such method has been discovered.
Women in the Cannabis Industry: Stay StrongSeptember 20, 2018
Who’s Buying All That Pot? A Look at the Demographics of Cannabis ConsumersSeptember 19, 2018
How to Grow Cannabis 142 – How to Sex Your PlantsSeptember 18, 2018
How to Grow Cannabis 219 – Integrated Pest ManagementSeptember 17, 2018
Do you want to receive the next Grower’s Spotlight as soon as it’s available? Sign up below!
- Want to learn more about subjects touched upon in this article? Check out our articles on subjects such as:
- Inside Look at Leading AZ Extraction Company
- Treatise on Decarboxylation: Part One
- Treatise on Decarboxylation: Part Two
- Smoking vs Eating Cannabis: The Effects on Patient Health: Part One
- Smoking vs Eating Cannabis: The Effects on Patient Health: Part Two
- Smoking vs Eating Cannabis: The Effects on Patient Health: Part Three
- Want to get in touch with Savino? He can be reached via the following methods:
Do you have any questions or comments?
About the Author
Savino Sguera is founder and CSO of Digamma Consulting. Since 2010 he has been an analytical chemist and researcher in the cannabis industry, working with both private and public interests to bring scientific integrity to the business. Savino holds a B.Sci. in Biomedical Engineering from Columbia University.